Abstract：
Cellular therapy is considered a better option for the treatment of degenerative disorders. Different cell types are being used for tissue regeneration. Despite extensive research in this field, several issues remain to be addressed concerning cell transplantation. One of these issues is the survival and homing of administered cells in the injured tissue, which depends on the ability of these cells to adhere. To enhance cell adherence and survival, Rap1 GTPase was activated in mesenchymal stem cells (MSCs) as well as in cardiomyocytes (CMs) by using 8-pCPT-2\'-O-Me-cAMP, and the effect on gene expression dynamics was determined through quantitative reverse transcriptase-polymerase chain reaction analysis. Pharmacological activation of MSCs and CMs resulted in the upregulation of connexin-43 and cell adhesion genes, which increased the cell adhesion ability of MSCs and CMs, and increased the fusion of MSCs with neonatal CMs. Treating stem cells with a pharmacological agent that activates Rap1a before transplantation can enhance their fusion with CMs and increase cellular regeneration.
摘要：
细胞疗法被认为是治疗退行性疾病的更好选择。不同的细胞类型用于组织再生。尽管在这一领域进行了广泛的研究，关于细胞移植的几个问题仍有待解决。这些问题之一是受损组织中施用细胞的存活和归巢，这取决于这些细胞的粘附能力。为了增强细胞粘附和存活，通过使用8-pCPT-2\'-O-Me-cAMP，在间充质干细胞（MSC）和心肌细胞（CM）中激活Rap1GTP酶，并通过定量逆转录酶-聚合酶链反应分析确定对基因表达动力学的影响。MSCs和CMs的药理学激活导致连接蛋白-43和细胞粘附基因的上调,增加了MSCs和CMs的细胞粘附能力，并增加了MSCs与新生儿CMs的融合。在移植前用激活Rap1a的药物处理干细胞可以增强其与CMs的融合并增加细胞再生。
